[{"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-001", "question": "A 68-year-old man is 18 days post-Ivor Lewis esophagectomy with gastric conduit reconstruction for stage III esophageal adenocarcinoma. He develops sudden onset cough with swallowing, respiratory distress, and sepsis. Chest CT demonstrates a 5 mm fistula between the gastric conduit and right mainstem bronchus at the level of the carina, with surrounding mediastinal air and fluid. Bronchoscopy confirms the fistula with conduit mucosa visible. What is the definitive management?", "options": ["A) Endoscopic placement of overlapping esophageal and airway stents", "B) Emergency right thoracotomy with fistula repair using intercostal muscle flap and conduit resection with cervical esophagostomy", "C) NPO status, total parenteral nutrition, and broad-spectrum antibiotics for 6 weeks", "D) Bronchoscopic application of fibrin glue and continued enteral feeding via jejunostomy", "E) Cervical esophagostomy and conduit abandonment without fistula repair"], "answer": "B", "answer_index": 1, "explanation": "Early postoperative tracheobronchial-gastric conduit fistula requires urgent surgical repair with viable muscle flap reinforcement; conduit ischemia at the anastomotic line necessitates conduit resection and delayed reconstruction. Endoscopic stenting has >80% failure rate in this setting due to conduit tension and ongoing contamination.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. Key stem clues: 18 days post-Ivor Lewis esophagectomy (early postoperative window), 5 mm gastric conduit-right mainstem bronchus fistula at carina, mediastinal air/fluid, respiratory distress, and sepsis. These findings define a life-threatening anastomotic leak with airway involvement requiring urgent source control and definitive closure. Surgical repair with intercostal muscle flap is the standard for early fistulas, especially with hemodynamic/respiratory compromise; conduit resection is justified when ischemia is suspected, as implied by early dehiscence. Alternative A (dual stenting) is inferior in the early postoperative period due to high failure rates from inflammation and conduit tension, as correctly noted. Option C (conservative therapy) cannot control mediastinal sepsis in an unstable patient. Option D (fibrin glue) is inadequate for a 5 mm contaminated defect. Option E leaves the fistula unrepaired, perpetuating sepsis. No internal contradictions; the stem provides sufficient discriminatory detail. Medical accuracy aligns with thoracic surgery consensus: emergency surgical repair is definitive management for early postoperative tracheobronchial fistula with systemic compromise. The rationale accurately reflects guideline-based practice. Minimal fix: none required; item is board-ready.\",\"medical_accuracy_score\":   \t\"4\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. Key stem clues: 18 days post-Ivor Lewis esophagectomy (early postoperative window), 5 mm gastric conduit-right mainstem bronchus fistula at carina, mediastinal air/fluid, respiratory distress, and sepsis. These findings define a life-threatening anastomotic leak with airway involvement requiring urgent source control and definitive closure. Surgical repair with intercostal muscle flap is the standard for early fistulas, especially with hemodynamic/respiratory compromise; conduit resection is justified when ischemia is suspected, as implied by early dehiscence. Alternative A (dual stenting) is inferior in the early postoperative period due to high failure rates from inflammation and conduit tension, as correctly noted. Option C (conservative therapy) cannot control mediastinal sepsis in an unstable patient. Option D (fibrin glue) is inadequate for a 5 mm contaminated defect. Option E leaves the fistula unrepaired, perpetuating sepsis. No internal contradictions; the stem provides sufficient discriminatory detail. Medical accuracy aligns with thoracic surgery consensus: emergency surgical repair is definitive management for early postoperative tracheobronchial fistula with systemic compromise. The rationale accurately reflects guideline-based practice. Minimal fix: none required; item is board-ready.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-002", "question": "A 54-year-old woman with antiphospholipid syndrome presents with 12 hours of severe epigastric pain and vomiting. CT angiography demonstrates thrombosis of the superior mesenteric vein extending into the intrahepatic portal veins, bowel wall thickening with pneumatosis of the proximal jejunum, and ascites. Exploratory laparotomy reveals dusky but viable small bowel without frank necrosis. What is the most appropriate next step?", "options": ["A) Resection of all affected bowel and mesenteric venous thrombectomy", "B) Systemic unfractionated heparin infusion targeting aPTT 2-3x control", "C) Catheter-directed thrombolysis of the superior mesenteric vein with alteplase via transhepatic approach", "D) Therapeutic enoxaparin 1 mg/kg twice daily and second-look laparotomy in 24 hours", "E) Mesenteric venous stent placement across the thrombosed segment"], "answer": "C", "answer_index": 2, "explanation": "In acute mesenteric venous thrombosis with bowel ischemia but viable intestine, catheter-directed thrombolysis restores venous outflow and prevents progression to infarction. Systemic anticoagulation alone is insufficient for extensive thrombus; surgical thrombectomy is ineffective and causes major bleeding.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: K (miskeyed); secondary U (underspecified) and M (multiple defensible). Verdict: The keyed answer C is not the best answer; D is more appropriate. Key stem clues: acute SMV thrombosis with intrahepatic extension, bowel wall thickening, pneumatosis, viable but dusky bowel on laparotomy, antiphospholipid syndrome. Main logical issue: The item does not provide sufficient detail to justify thrombolysis over anticoagulation; systemic heparin (B) or LMWH with second‑look (D) are equally defensible, making the key unsupported. Main medical accuracy issue: Current guidelines (ACG, SVS) recommend immediate systemic anticoagulation as first‑line therapy for MVT; catheter‑directed thrombolysis is reserved for selected cases with persistent ischemia despite anticoagulation. The rationale that systemic anticoagulation is insufficient for extensive thrombus is inaccurate. Minimal fix: Change the key to D and revise the rationale to state that therapeutic LMWH plus planned second‑look laparotomy is the standard next step after laparotomy for viable but ischemic bowel in the setting of antiphospholipid syndrome.\",\n\"medical_accuracy_score\":   \t\"2\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: K (miskeyed); secondary U (underspecified) and M (multiple defensible). Verdict: The keyed answer C is not the best answer; D is more appropriate. Key stem clues: acute SMV thrombosis with intrahepatic extension, bowel wall thickening, pneumatosis, viable but dusky bowel on laparotomy, antiphospholipid syndrome. Main logical issue: The item does not provide sufficient detail to justify thrombolysis over anticoagulation; systemic heparin (B) or LMWH with second‑look (D) are equally defensible, making the key unsupported. Main medical accuracy issue: Current guidelines (ACG, SVS) recommend immediate systemic anticoagulation as first‑line therapy for MVT; catheter‑directed thrombolysis is reserved for selected cases with persistent ischemia despite anticoagulation. The rationale that systemic anticoagulation is insufficient for extensive thrombus is inaccurate. Minimal fix: Change the key to D and revise the rationale to state that therapeutic LMWH plus planned second‑look laparotomy is the standard next step after laparotomy for viable but ischemic bowel in the setting of antiphospholipid syndrome.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-003", "question": "A 42-year-old man with MEN1 syndrome (germline MEN1 c.628_631del) is found to have a 2.8 cm duodenal gastrinoma with 3 regional periduodenal lymph node metastases on Ga-68 DOTATATE PET/CT. Serum gastrin is 2,200 pg/mL with gastric pH <2. He has no pancreatic lesions. What is the optimal surgical management?", "options": ["A) Whipple pancreaticoduodenectomy with pylorus preservation", "B) Pancreas-preserving duodenectomy with regional lymphadenectomy", "C) Endoscopic submucosal dissection of the duodenal tumor", "D) Long-acting octreotide 30 mg monthly without surgery", "E) Tumor enucleation through duodenotomy only"], "answer": "B", "answer_index": 1, "explanation": "For large duodenal neuroendocrine tumors in MEN1, pancreas-preserving duodenectomy achieves oncologic clearance while preserving pancreatic function, which is critical as these patients inevitably develop pancreatic neuroendocrine tumors requiring future pancreatic surgery. Whipple procedure is excessively morbid for duodenal disease alone.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V (valid). Verdict: The keyed answer B is the correct best answer. The stem provides a classic MEN1-associated duodenal gastrinoma (2.8 cm) with regional nodal metastases and no pancreatic involvement. Key discriminating clues are tumor size >2 cm, nodal disease, and absence of pancreatic lesions, which direct toward surgical resection that preserves pancreatic parenchyma. Option B (pancreas‑preserving duodenectomy with regional lymphadenectomy) aligns with ENETS/AAES guidelines for duodenal NETs in MEN1 when the pancreas is uninvolved, balancing oncologic clearance and future pancreatic surgery risk. Options A (Whipple) is unnecessarily morbid for isolated duodenal disease; C (endoscopic resection) is inadequate for size and nodal disease; D (octreotide alone) is non‑curative; E (enucleation) does not address nodal metastases. No internal contradictions; only one option is defensible. Medical accuracy: The item reflects current consensus, emphasizing preservation of pancreatic function in MEN1 patients. No major inaccuracies. Minimal fix: None required; the item is already unambiguous and accurate.\",\n\"medical_accuracy_score\":   \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (valid). Verdict: The keyed answer B is the correct best answer. The stem provides a classic MEN1-associated duodenal gastrinoma (2.8 cm) with regional nodal metastases and no pancreatic involvement. Key discriminating clues are tumor size >2 cm, nodal disease, and absence of pancreatic lesions, which direct toward surgical resection that preserves pancreatic parenchyma. Option B (pancreas‑preserving duodenectomy with regional lymphadenectomy) aligns with ENETS/AAES guidelines for duodenal NETs in MEN1 when the pancreas is uninvolved, balancing oncologic clearance and future pancreatic surgery risk. Options A (Whipple) is unnecessarily morbid for isolated duodenal disease; C (endoscopic resection) is inadequate for size and nodal disease; D (octreotide alone) is non‑curative; E (enucleation) does not address nodal metastases. No internal contradictions; only one option is defensible. Medical accuracy: The item reflects current consensus, emphasizing preservation of pancreatic function in MEN1 patients. No major inaccuracies. Minimal fix: None required; the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-004", "question": "A 62-year-old man develops painful hepatomegaly, ascites, and jaundice 3 weeks after completing 6 cycles of FOLFOX adjuvant chemotherapy for colon cancer. Total bilirubin is 8.2 mg/dL, ALT 450 U/L, INR 1.8. Liver biopsy shows sinusoidal congestion, hepatocyte necrosis zone 3, and absence of portal inflammation. What is the definitive therapy?", "options": ["A) High-dose methylprednisolone 1 mg/kg/day and diuretics", "B) Defibrotide 25 mg/kg/day IV in divided doses for 21 days", "C) Transjugular intrahepatic portosystemic shunt (TIPS) placement", "D) N-acetylcysteine 150 mg/kg IV bolus then continuous infusion", "E) Urgent liver transplant evaluation"], "answer": "B", "answer_index": 1, "explanation": "Severe sinusoidal obstruction syndrome from oxaliplatin requires defibrotide, which restores thrombomodulin expression and promotes fibrinolysis. TIPS is contraindicated due to diffuse sinusoidal injury; steroids are ineffective. Transplant is reserved for fulminant hepatic failure with encephalopathy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. The vignette describes classic severe sinusoidal obstruction syndrome (SOS/VOD) post-oxaliplatin with painful hepatomegaly, ascites, hyperbilirubinemia (8.2 mg/dL), coagulopathy (INR 1.8), and pathognomonic biopsy findings of sinusoidal congestion with zone 3 necrosis and absent portal inflammation. These findings uniquely point to severe SOS/VOD, for which defibrotide (option B) is the established disease-specific therapy. Alternative options are appropriately excluded: high-dose steroids (no role in SOS/VOD pathophysiology), TIPS (contraindicated due to diffuse sinusoidal injury and risk of worsening hepatocellular necrosis), N-acetylcysteine (specific for acetaminophen-induced injury), and urgent transplant evaluation (reserved for fulminant hepatic failure with encephalopathy, which is explicitly absent). The item provides sufficient discriminators for a single best answer without requiring unstated assumptions. Medical accuracy is gold-standard: defibrotide dosing (25 mg/kg/day × 21 days) and mechanism (restoring thrombomodulin, promoting fibrinolysis) align with current guidelines and literature. The rationale correctly states management principles. No revisions needed.\",\"medical_accuracy_score\":   \"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. The vignette describes classic severe sinusoidal obstruction syndrome (SOS/VOD) post-oxaliplatin with painful hepatomegaly, ascites, hyperbilirubinemia (8.2 mg/dL), coagulopathy (INR 1.8), and pathognomonic biopsy findings of sinusoidal congestion with zone 3 necrosis and absent portal inflammation. These findings uniquely point to severe SOS/VOD, for which defibrotide (option B) is the established disease-specific therapy. Alternative options are appropriately excluded: high-dose steroids (no role in SOS/VOD pathophysiology), TIPS (contraindicated due to diffuse sinusoidal injury and risk of worsening hepatocellular necrosis), N-acetylcysteine (specific for acetaminophen-induced injury), and urgent transplant evaluation (reserved for fulminant hepatic failure with encephalopathy, which is explicitly absent). The item provides sufficient discriminators for a single best answer without requiring unstated assumptions. Medical accuracy is gold-standard: defibrotide dosing (25 mg/kg/day × 21 days) and mechanism (restoring thrombomodulin, promoting fibrinolysis) align with current guidelines and literature. The rationale correctly states management principles. No revisions needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-005", "question": "A 35-year-old woman with CFH p.Arg1215Gln mutation undergoes deceased donor kidney transplantation. On postoperative day 7, she develops rising creatinine (3.4 mg/dL), thrombocytopenia (45,000/μL), schistocytes, and hemolysis. Eculizumab 900 mg weekly was started preemptively on day 0. Platelets normalize by day 10 but creatinine continues to rise to 4.8 mg/dL. What is the next step?", "options": ["A) Increase eculizumab dose to 1,200 mg weekly", "B) Initiate daily plasma exchange with fresh frozen plasma", "C) Switch to ravulizumab 3,600 mg maintenance dose", "D) Measure eculizumab trough level and CH50 activity", "E) Proceed with transplant nephrectomy"], "answer": "D", "answer_index": 3, "explanation": "Breakthrough atypical HUS despite eculizumab requires therapeutic drug monitoring to distinguish underdosing from complement amplification via properdin or C5 gain-of-function mutation. Pharmacokinetic assessment guides therapy rather than empiric dose escalation or ineffective plasma exchange.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V (Valid). Verdict: The keyed answer D is the correct best answer. The stem provides a classic scenario of breakthrough atypical HUS (aHUS) after kidney transplantation despite prophylactic eculizumab. Key discriminating clues are: (1) known CFH p.Arg1215Gln mutation predisposing to aHUS; (2) preemptive eculizumab 900 mg weekly; (3) new thrombocytopenia, schistocytes, and hemolysis on postoperative day 7; (4) platelet count normalizes by day 10, indicating partial complement blockade; (5) creatinine continues to rise, suggesting inadequate local (renal) C5 inhibition or alternative complement amplification. The next logical step is to assess whether therapeutic concentrations of eculizumab are present and whether complement activity is suppressed. Measuring eculizumab trough level and CH50 activity (option D) directly informs whether the failure is pharmacokinetic (underdosing) or pharmacodynamic (e.g., C5 gain‑of‑function, properdin‑mediated amplification), guiding subsequent therapy (dose escalation, switch to ravulizumab, or adjunctive plasma exchange). Options A, B, C, and E are less appropriate without this information: empiric dose escalation may be unnecessary, plasma exchange is less effective, switching to ravulizumab is premature, and nephrectomy is overtly aggressive. No internal contradictions or missing critical details prevent a single best answer. Medical accuracy is high: the approach aligns with current aHUS management guidelines and transplant literature. No fix required.\",\n\"medical_accuracy_score\":  \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict: The keyed answer D is the correct best answer. The stem provides a classic scenario of breakthrough atypical HUS (aHUS) after kidney transplantation despite prophylactic eculizumab. Key discriminating clues are: (1) known CFH p.Arg1215Gln mutation predisposing to aHUS; (2) preemptive eculizumab 900 mg weekly; (3) new thrombocytopenia, schistocytes, and hemolysis on postoperative day 7; (4) platelet count normalizes by day 10, indicating partial complement blockade; (5) creatinine continues to rise, suggesting inadequate local (renal) C5 inhibition or alternative complement amplification. The next logical step is to assess whether therapeutic concentrations of eculizumab are present and whether complement activity is suppressed. Measuring eculizumab trough level and CH50 activity (option D) directly informs whether the failure is pharmacokinetic (underdosing) or pharmacodynamic (e.g., C5 gain‑of‑function, properdin‑mediated amplification), guiding subsequent therapy (dose escalation, switch to ravulizumab, or adjunctive plasma exchange). Options A, B, C, and E are less appropriate without this information: empiric dose escalation may be unnecessary, plasma exchange is less effective, switching to ravulizumab is premature, and nephrectomy is overtly aggressive. No internal contradictions or missing critical details prevent a single best answer. Medical accuracy is high: the approach aligns with current aHUS management guidelines and transplant literature. No fix required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-006", "question": "A 28-year-old man is day +45 after matched unrelated donor allogeneic stem cell transplant for AML in CR1. He develops new hypertension (BP 165/100 mmHg), proteinuria (3.2 g/day), rising LDH (850 U/L), hemolysis, and thrombocytopenia. ADAMTS13 activity is 45%. Tacrolimus was stopped 14 days ago for rising creatinine. What is the appropriate therapy?", "options": ["A) Eculizumab 900 mg weekly IV", "B) High-dose methylprednisolone 1 g IV x3 days plus plasma exchange", "C) Rituximab 375 mg/m2 weekly for 4 doses", "D) Resume tacrolimus and target level 8-10 ng/mL", "E) Supportive care with aggressive blood pressure control only"], "answer": "A", "answer_index": 0, "explanation": "Transplant-associated thrombotic microangiopathy is mediated by complement activation independent of ADAMTS13; eculizumab blocks terminal complement and is the only effective therapy. Plasma exchange is ineffective; resuming calcineurin inhibitors worsens TMA.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V – the stem provides a classic picture of transplant‑associated thrombotic microangiopathy (TA‑TMA) after allogeneic HSCT: new hypertension, proteinuria, rising LDH, hemolysis and thrombocytopenia with an ADAMTS13 activity that is not severely deficient (45 %). The discontinuation of tacrolimus 14 days ago removes a drug‑induced TMA trigger, pointing to complement‑mediated injury. Among the choices, eculizumab (anti‑C5) directly targets the underlying complement activation and is the only option with proven efficacy for complement‑mediated TMA. High‑dose steroids + plasma exchange (choice B) and rituximab (C) are treatments for TTP, which is unlikely here. Resuming tacrolimus (D) would aggravate TMA, and supportive care alone (E) is insufficient for this severe presentation. Therefore a single best answer is defensible and matches the key. Medical accuracy: The vignette and dosing are consistent with current off‑label use of eculizumab for TA‑TMA; however, the claim that eculizumab is the “only effective therapy” overstates the evidence, as plasma exchange may still be used in some centers. This minor overstatement does not undermine the best‑answer selection. Logical issues: None; the stem discriminates clearly. Minimal fix: Add “(normal > 50 %)” after the ADAMTS13 value to explicitly rule out TTP and reinforce the complement‑mediated mechanism.\",\n\"medical_accuracy_score\":   \t\"4\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V – the stem provides a classic picture of transplant‑associated thrombotic microangiopathy (TA‑TMA) after allogeneic HSCT: new hypertension, proteinuria, rising LDH, hemolysis and thrombocytopenia with an ADAMTS13 activity that is not severely deficient (45 %). The discontinuation of tacrolimus 14 days ago removes a drug‑induced TMA trigger, pointing to complement‑mediated injury. Among the choices, eculizumab (anti‑C5) directly targets the underlying complement activation and is the only option with proven efficacy for complement‑mediated TMA. High‑dose steroids + plasma exchange (choice B) and rituximab (C) are treatments for TTP, which is unlikely here. Resuming tacrolimus (D) would aggravate TMA, and supportive care alone (E) is insufficient for this severe presentation. Therefore a single best answer is defensible and matches the key. Medical accuracy: The vignette and dosing are consistent with current off‑label use of eculizumab for TA‑TMA; however, the claim that eculizumab is the “only effective therapy” overstates the evidence, as plasma exchange may still be used in some centers. This minor overstatement does not undermine the best‑answer selection. Logical issues: None; the stem discriminates clearly. Minimal fix: Add “(normal > 50 %)” after the ADAMTS13 value to explicitly rule out TTP and reinforce the complement‑mediated mechanism.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-007", "question": "A 14-year-old girl with chronic atypical neutrophilic dermatosis, lipodystrophy, and recurrent fevers (CANDLE syndrome) has persistent inflammatory lesions and fevers despite anakinra 100 mg daily and canakinumab 150 mg monthly. Genetic testing confirms PSMB8 c.224C>T mutation. What is the next therapy?", "options": ["A) High-dose prednisone 1 mg/kg/day", "B) Baricitinib 4 mg daily (JAK1/2 inhibitor)", "C) Tocilizumab 8 mg/kg IV monthly", "D) Thalidomide 100 mg nightly", "E) Allogeneic stem cell transplant"], "answer": "B", "answer_index": 1, "explanation": "CANDLE syndrome is a type I interferonopathy due to proteasome dysfunction; JAK inhibitors block downstream interferon signaling and are effective when IL-1 blockade fails. Baricitinib has shown efficacy in refractory cases. Anti-IL-6 and thalidomide are ineffective; transplant is experimental.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues driving a unique best answer: (1) Genetically confirmed CANDLE syndrome (PSMB8 c.224C>T mutation) establishing a type I interferonopathy; (2) Documented failure of both anakinra and canakinumab (exhausting IL-1 blockade at standard doses); (3) Ongoing inflammatory burden requiring mechanism-directed escalation. These findings uniquely point to targeting the interferon signaling cascade downstream via JAK inhibition. Main logical issue(s): None; the stem provides clear mechanism-based rationale that discriminates all options. Main medical accuracy issue(s): None; baricitinib is supported by case series for refractory CANDLE syndrome, with 4 mg daily appropriate for adolescents ≥40 kg. Alternative evaluation: High-dose prednisone (A) is non-specific and unsuitable for chronic control; tocilizumab (C) incorrectly targets IL-6 rather than the interferon axis; thalidomide (D) lacks evidence; allogeneic stem cell transplant (E) is experimental and premature as next-line therapy. Minimal fix: No edit required; item is board-ready and clinically accurate.\",\"medical_accuracy_score\":   \t\"5\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues driving a unique best answer: (1) Genetically confirmed CANDLE syndrome (PSMB8 c.224C>T mutation) establishing a type I interferonopathy; (2) Documented failure of both anakinra and canakinumab (exhausting IL-1 blockade at standard doses); (3) Ongoing inflammatory burden requiring mechanism-directed escalation. These findings uniquely point to targeting the interferon signaling cascade downstream via JAK inhibition. Main logical issue(s): None; the stem provides clear mechanism-based rationale that discriminates all options. Main medical accuracy issue(s): None; baricitinib is supported by case series for refractory CANDLE syndrome, with 4 mg daily appropriate for adolescents ≥40 kg. Alternative evaluation: High-dose prednisone (A) is non-specific and unsuitable for chronic control; tocilizumab (C) incorrectly targets IL-6 rather than the interferon axis; thalidomide (D) lacks evidence; allogeneic stem cell transplant (E) is experimental and premature as next-line therapy. Minimal fix: No edit required; item is board-ready and clinically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-008", "question": "A 38-year-old man from Vietnam with chronic mucocutaneous candidiasis is found to have STAT1 gain-of-function c.821T>C mutation. He presents with disseminated umbilicated papular skin lesions, hepatosplenomegaly, and fevers. Skin biopsy shows intracellular yeast forms with central septation. What is optimal therapy?", "options": ["A) Liposomal amphotericin B 5 mg/kg/day alone for 14 days", "B) Voriconazole 6 mg/kg IV q12h then 4 mg/kg maintenance", "C) Liposomal amphotericin B induction then itraconazole maintenance plus ruxolitinib 10 mg BID", "D) Caspofungin 70 mg loading then 50 mg daily", "E) Fluconazole 800 mg loading then 400 mg daily"], "answer": "C", "answer_index": 2, "explanation": "STAT1 GOF causes defective Th17 immunity leading to refractory dimorphic fungal infections. Talaromyces marneffei requires initial amphotericin induction followed by itraconazole maintenance. Adding JAK inhibition (ruxolitinib) reverses the underlying immunodeficiency and is essential for cure.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: The keyed answer (C) is the unique best choice among the options. Key stem clues: Vietnam origin, umbilicated papules, hepatosplenomegaly, intracellular yeast with central septation—classic for Talaromyces marneffei; STAT1 GOF predisposes to refractory dimorphic fungi. Standard therapy is liposomal amphotericin B induction followed by itraconazole maintenance; other options are incorrect (amphotericin alone lacks maintenance, voriconazole/fluconazole/caspofungin have poor activity). The addition of ruxolitinib is nonstandard and not proven essential; the item overstates its role. No internal contradictions; options are mutually exclusive and allow clear discrimination. Medical accuracy: The antifungal regimen is correct, but the claim that ruxolitinib is essential is not supported by current guidelines; it is an experimental adjunct. This is a minor issue. Minimal fix: Delete “plus ruxolitinib 10 mg BID” from option C, leaving the standard antifungal regimen.\",\"medical_accuracy_score\":  \t\"3\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: The keyed answer (C) is the unique best choice among the options. Key stem clues: Vietnam origin, umbilicated papules, hepatosplenomegaly, intracellular yeast with central septation—classic for Talaromyces marneffei; STAT1 GOF predisposes to refractory dimorphic fungi. Standard therapy is liposomal amphotericin B induction followed by itraconazole maintenance; other options are incorrect (amphotericin alone lacks maintenance, voriconazole/fluconazole/caspofungin have poor activity). The addition of ruxolitinib is nonstandard and not proven essential; the item overstates its role. No internal contradictions; options are mutually exclusive and allow clear discrimination. Medical accuracy: The antifungal regimen is correct, but the claim that ruxolitinib is essential is not supported by current guidelines; it is an experimental adjunct. This is a minor issue. Minimal fix: Delete “plus ruxolitinib 10 mg BID” from option C, leaving the standard antifungal regimen.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-009", "question": "A 65-year-old man with metastatic melanoma on ipilimumab 3 mg/kg plus nivolumab 1 mg/kg presents with severe fatigue, hypotension (BP 85/50 mmHg), hyponatremia (Na 122 mEq/L), and headache. Troponin I is 15 ng/mL with normal EF 55%. Brain MRI shows diffuse pituitary enlargement with homogeneous enhancement. What is immediate management?", "options": ["A) Methylprednisolone 1 mg/kg/day IV alone", "B) Methylprednisolone 1 mg/kg/day plus infliximab 5 mg/kg", "C) Methylprednisolone 1 mg/kg/day plus mycophenolate mofetil 1 g BID", "D) Methylprednisolone 1 g IV x3 days plus anti-thymocyte globulin", "E) Hold immunotherapy and initiate supportive care only"], "answer": "C", "answer_index": 2, "explanation": "Combined hypophysitis and myocarditis from dual checkpoint inhibition requires high-dose steroids. Mycophenolate mofetil is preferred for steroid-refractory myocarditis as infliximab can worsen myocardial inflammation. Anti-thymocyte globulin is overly immunosuppressive in this setting.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: K (Miskeyed). Verdict: The keyed answer (C) is not the best immediate management. The stem describes a patient with dual checkpoint inhibitor–related hypophysitis (hypotension, hyponatremia, pituitary enlargement) and myocarditis (elevated troponin). The immediate priority is high‑dose glucocorticoids (methylprednisolone 1 mg/kg/day IV) to treat both adrenal crisis and myocarditis. Mycophenolate mofetil is a second‑line agent for steroid‑refractory myocarditis and is not part of initial therapy. Therefore option A, not C, is the single best answer. The other options are less appropriate: B includes infliximab, which can worsen myocardial inflammation; D adds overly aggressive anti‑thymocyte globulin; E omits essential steroids. The item is internally consistent and allows a unique best answer, but the key mismatches it. Main logical issue: miskeying. Main medical accuracy issue: the answer explanation conflates immediate management with steroid‑refractory management, misapplying guideline nuance. Minimal fix: Change the correct answer to A and revise the rationale to state that immediate therapy is high‑dose steroids alone, with mycophenolate reserved for non‑responders.\",\n\"medical_accuracy_score\":   \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \t\t\t\t\t\t \"3\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"K\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: The keyed answer (C) is not the best immediate management. The stem describes a patient with dual checkpoint inhibitor–related hypophysitis (hypotension, hyponatremia, pituitary enlargement) and myocarditis (elevated troponin). The immediate priority is high‑dose glucocorticoids (methylprednisolone 1 mg/kg/day IV) to treat both adrenal crisis and myocarditis. Mycophenolate mofetil is a second‑line agent for steroid‑refractory myocarditis and is not part of initial therapy. Therefore option A, not C, is the single best answer. The other options are less appropriate: B includes infliximab, which can worsen myocardial inflammation; D adds overly aggressive anti‑thymocyte globulin; E omits essential steroids. The item is internally consistent and allows a unique best answer, but the key mismatches it. Main logical issue: miskeying. Main medical accuracy issue: the answer explanation conflates immediate management with steroid‑refractory management, misapplying guideline nuance. Minimal fix: Change the correct answer to A and revise the rationale to state that immediate therapy is high‑dose steroids alone, with mycophenolate reserved for non‑responders.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-010", "question": "A 42-year-old woman with lifelong idiopathic anaphylaxis, chronic urticaria, joint hypermobility, and baseline serum tryptase of 35 ng/mL is found to have heterozygous TPSAB1 copy number gain (α-tryptasemia). Symptoms persist despite high-dose cetirizine 40 mg daily and omalizumab 300 mg monthly. What is next therapy?", "options": ["A) Increase omalizumab to 600 mg monthly", "B) Prophylactic prednisone 10 mg daily", "C) Cromolyn sodium 200 mg QID", "D) Ketotifen 2 mg BID (mast cell stabilizer)", "E) Allergen immunotherapy based on skin testing"], "answer": "D", "answer_index": 3, "explanation": "Hereditary Alpha-Tryptasemia Syndrome causes constitutive mast cell activation; ketotifen stabilizes mast cell membranes and is effective when antihistamines fail. Omalizumab has variable efficacy; cromolyn is poorly absorbed systemically. Steroids are not prophylactic therapy.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). Verdict: Correct best answer. This stem describes Hereditary Alpha-Tryptasemia Syndrome (HαTS) with refractory anaphylaxis/urticaria despite high-dose antihistamine and omalizumab. Key clues: elevated baseline tryptase (35 ng/mL), TPSAB1 copy gain, persistent systemic mast cell activation symptoms. The question asks for next therapy after standard agents fail. Ketotifen (D) is defensible as a mast cell stabilizer with systemic activity, commonly used in mast cell activation disorders. Alternative analysis: (A) Omalizumab dose escalation lacks evidence and is non-standard; (B) Prophylactic steroids are discouraged due to toxicity; (C) Cromolyn has poor oral bioavailability and limited systemic efficacy; (E) Immunotherapy is contraindicated in idiopathic anaphylaxis. No internal contradictions exist, and D is uniquely best. Medical accuracy is excellent: reflects current understanding of HαTS management, appropriately dismisses other options with valid reasoning. Minor nuance: some experts might consider leukotriene antagonists before ketotifen, but ketotifen remains a well-accepted next step. Minimal fix: None required; item is board-ready.\",\"medical_accuracy_score\":    \t\"5\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict: Correct best answer. This stem describes Hereditary Alpha-Tryptasemia Syndrome (HαTS) with refractory anaphylaxis/urticaria despite high-dose antihistamine and omalizumab. Key clues: elevated baseline tryptase (35 ng/mL), TPSAB1 copy gain, persistent systemic mast cell activation symptoms. The question asks for next therapy after standard agents fail. Ketotifen (D) is defensible as a mast cell stabilizer with systemic activity, commonly used in mast cell activation disorders. Alternative analysis: (A) Omalizumab dose escalation lacks evidence and is non-standard; (B) Prophylactic steroids are discouraged due to toxicity; (C) Cromolyn has poor oral bioavailability and limited systemic efficacy; (E) Immunotherapy is contraindicated in idiopathic anaphylaxis. No internal contradictions exist, and D is uniquely best. Medical accuracy is excellent: reflects current understanding of HαTS management, appropriately dismisses other options with valid reasoning. Minor nuance: some experts might consider leukotriene antagonists before ketotifen, but ketotifen remains a well-accepted next step. Minimal fix: None required; item is board-ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-011", "question": "A 57-year-old man is 6 hours status post bilateral sequential lung transplantation for idiopathic pulmonary fibrosis. He remains on 100% FiO2 with PaO2/FiO2 ratio of 85 despite inhaled nitric oxide at 40 ppm and optimal ventilator settings. Chest X-ray shows diffuse bilateral infiltrates. What is the optimal mechanical support strategy?", "options": ["A) Veno-venous ECMO via femoral-jugular cannulation", "B) Veno-arterial ECMO via central cannulation", "C) Extracorporeal CO2 removal with 1 L/min blood flow", "D) Inhaled epoprostenol 50 ng/kg/min only", "E) Veno-venous ECMO via dual-lumen cannula (Avalon) in right internal jugular vein"], "answer": "E", "answer_index": 4, "explanation": "Severe primary graft dysfunction grade 3 requires full respiratory support. Dual-lumen single-site VV-ECMO (Avalon) allows early mobilization and rehabilitation, which improves long-term outcomes. Femoral-jugular configuration limits mobility; VA-ECMO is unnecessary without cardiac failure.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Thoracic Surgery", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. Stem depicts severe PGD grade 3 (PaO2/FiO2 85, diffuse infiltrates) after bilateral lung transplant without cardiac failure. Key discriminating factor: 'optimal' support implies maximizing long-term outcomes, not just gas exchange. VV-ECMO is indicated, eliminating B (unnecessary cardiac support), C (insufficient oxygenation), and D (inadequate). Between VV-ECMO configurations, dual-lumen Avalon (E) enables early mobilization and rehabilitation, which improves outcomes; femoral-jugular (A) limits mobility. The rationale correctly prioritizes this advantage. No contradictions; vascular anatomy feasibility is reasonably assumed absent contraindications. Medical accuracy: 4—content aligns with modern ECMO management and PGD treatment standards. The superiority of E over A is defensible but depends on institutional capability and anatomy not stated. Minimal fix: add 'in a center experienced with dual-lumen cannulation and early mobilization protocols' to the stem to solidify the optimality claim and reduce ambiguity.\",\"medical_accuracy_score\":   \"4\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. Stem depicts severe PGD grade 3 (PaO2/FiO2 85, diffuse infiltrates) after bilateral lung transplant without cardiac failure. Key discriminating factor: 'optimal' support implies maximizing long-term outcomes, not just gas exchange. VV-ECMO is indicated, eliminating B (unnecessary cardiac support), C (insufficient oxygenation), and D (inadequate). Between VV-ECMO configurations, dual-lumen Avalon (E) enables early mobilization and rehabilitation, which improves outcomes; femoral-jugular (A) limits mobility. The rationale correctly prioritizes this advantage. No contradictions; vascular anatomy feasibility is reasonably assumed absent contraindications. Medical accuracy: 4—content aligns with modern ECMO management and PGD treatment standards. The superiority of E over A is defensible but depends on institutional capability and anatomy not stated. Minimal fix: add 'in a center experienced with dual-lumen cannulation and early mobilization protocols' to the stem to solidify the optimality claim and reduce ambiguity.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-012", "question": "A 72-year-old man has a 5.5 cm infrarenal abdominal aortic aneurysm with a thick circumferential rind of periaortic inflammation, bilateral ureteral obstruction with hydronephrosis, and elevated ESR (85 mm/hr) and CRP (120 mg/L). What is the optimal management sequence?", "options": ["A) Immediate open surgical repair with prednisone 1 mg/kg", "B) Endovascular aortic repair (EVAR) then prednisone 1 mg/kg", "C) Prednisone 40 mg daily for 6 weeks then open surgical repair", "D) Prednisone 40 mg daily for 6 weeks then EVAR", "E) Prednisone alone without aortic repair"], "answer": "D", "answer_index": 3, "explanation": "Inflammatory AAA requires initial steroid therapy to reduce periaortic inflammation and relieve ureteral obstruction. Delayed EVAR is preferred over open repair due to severe periaortic inflammation that increases surgical morbidity. Steroids alone risk aneurysm rupture.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Vascular Surgery", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Keyed answer D is the correct best choice. Stem clues—5.5 cm infrarenal AAA (repair threshold), thick inflammatory rind, bilateral ureteral obstruction, and markedly elevated ESR/CRP—define inflammatory AAA with obstructive uropathy. Standard management: high-dose steroids first to reduce inflammation and relieve ureteral obstruction, followed by repair. EVAR is preferred over open repair because severe periaortic inflammation increases surgical morbidity. Option D correctly sequences steroids (6 weeks) then EVAR. Options A/B err by immediate repair before inflammation control. Option C correctly uses steroids but selects higher-risk open repair. Option E risks rupture. No logical flaws permit a single best answer. Minor medical accuracy issue: rationale states '1 mg/kg' while options specify '40 mg daily'—for a typical 70–80 kg man this is a slight underdose, but 40 mg is clinically used and does not invalidate the item. Minimal fix: Align rationale wording to 'high-dose steroids (e.g., prednisone 40–60 mg daily)' to match options.\",\"medical_accuracy_score\":   \t\"4\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Keyed answer D is the correct best choice. Stem clues—5.5 cm infrarenal AAA (repair threshold), thick inflammatory rind, bilateral ureteral obstruction, and markedly elevated ESR/CRP—define inflammatory AAA with obstructive uropathy. Standard management: high-dose steroids first to reduce inflammation and relieve ureteral obstruction, followed by repair. EVAR is preferred over open repair because severe periaortic inflammation increases surgical morbidity. Option D correctly sequences steroids (6 weeks) then EVAR. Options A/B err by immediate repair before inflammation control. Option C correctly uses steroids but selects higher-risk open repair. Option E risks rupture. No logical flaws permit a single best answer. Minor medical accuracy issue: rationale states '1 mg/kg' while options specify '40 mg daily'—for a typical 70–80 kg man this is a slight underdose, but 40 mg is clinically used and does not invalidate the item. Minimal fix: Align rationale wording to 'high-dose steroids (e.g., prednisone 40–60 mg daily)' to match options.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-013", "question": "A 58-year-old woman presents with a 4 cm pancreatic tail tumor, necrolytic migratory erythema, weight loss of 30 lbs, and new-onset diabetes. Biopsy confirms glucagonoma with Ki-67 8% and diffuse hepatic metastases on MRI. Serum glucagon is 2,500 pg/mL. What is first-line therapy?", "options": ["A) Distal pancreatectomy with splenectomy", "B) Octreotide LAR 30 mg intramuscular monthly", "C) Lanreotide autogel 120 mg deep subcutaneous every 4 weeks", "D) Everolimus 10 mg daily plus octreotide LAR", "E) Streptozocin 500 mg/m2 plus doxorubicin 50 mg/m2 every 3 weeks"], "answer": "C", "answer_index": 2, "explanation": "For metastatic glucagonoma, long-acting somatostatin analogs control hormone symptoms and have antiproliferative activity. Lanreotide 120 mg every 4 weeks is preferred over octreotide LAR due to consistent dosing. Everolimus is second-line; chemotherapy is reserved for progressive disease.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: M (multiple answers defensible). The stem describes a metastatic glucagonoma with diffuse hepatic metastases; first-line therapy is a long-acting somatostatin analog for symptom control and antiproliferative effect. Both octreotide LAR (option B) and lanreotide autogel (option C) are appropriate first-line choices; no clinical detail in the vignette distinguishes them. Therefore, more than one option is equally defensible, making the item logically invalid. The keyed answer (C) is not uniquely best. The rationale that lanreotide is preferred because of more consistent dosing is not supported by major guidelines (NCCN, ESMO), which consider the two agents equivalent; this introduces a minor medical accuracy issue. The remaining options are appropriately incorrect: surgery (A) is not indicated for diffuse metastases, everolimus (D) is second-line, and chemotherapy (E) is reserved for progressive disease. Minimal fix: remove option B (octreotide) or add a specific discriminating clue (e.g., prior intolerance to octreotide or patient preference for deep subcutaneous injection) to justify lanreotide as the preferred agent.\",\n\"medical_accuracy_score\":  \t\"3\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible). The stem describes a metastatic glucagonoma with diffuse hepatic metastases; first-line therapy is a long-acting somatostatin analog for symptom control and antiproliferative effect. Both octreotide LAR (option B) and lanreotide autogel (option C) are appropriate first-line choices; no clinical detail in the vignette distinguishes them. Therefore, more than one option is equally defensible, making the item logically invalid. The keyed answer (C) is not uniquely best. The rationale that lanreotide is preferred because of more consistent dosing is not supported by major guidelines (NCCN, ESMO), which consider the two agents equivalent; this introduces a minor medical accuracy issue. The remaining options are appropriately incorrect: surgery (A) is not indicated for diffuse metastases, everolimus (D) is second-line, and chemotherapy (E) is reserved for progressive disease. Minimal fix: remove option B (octreotide) or add a specific discriminating clue (e.g., prior intolerance to octreotide or patient preference for deep subcutaneous injection) to justify lanreotide as the preferred agent.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-014", "question": "A 35-year-old woman has chronic iron deficiency anemia requiring IV iron every 3 months, recurrent episodes of partial small bowel obstruction, and capsule endoscopy shows 5 short ulcerated strictures in the proximal jejunum. Biopsy shows superficial ulceration without granulomas, crypt distortion, or viral inclusions. What is the diagnosis and treatment?", "options": ["A) Crohn's disease: start infliximab", "B) NSAID enteropathy: stop all NSAIDs", "C) Cryptogenic multifocal ulcerous stenosing enteritis: budesonide 9 mg daily", "D) Small bowel lymphoma: R-CHOP chemotherapy", "E) Refractory celiac disease: cladribine"], "answer": "C", "answer_index": 2, "explanation": "Cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) is characterized by multiple short ulcerated strictures without transmural inflammation. Diagnosis requires exclusion of Crohn's disease and NSAID injury. Budesonide induces remission; anti-TNF agents are ineffective. Capsule retention risk requires patency assessment.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. Key stem clues: 35-year-old woman with chronic iron deficiency anemia requiring recurrent IV iron, recurrent partial SBO, capsule endoscopy showing 5 short ulcerated strictures in proximal jejunum, and biopsies demonstrating superficial ulceration without granulomas, crypt distortion, or viral inclusions. These findings are classic for cryptogenic multifocal ulcerous stenosing enteritis (CMUSE), a diagnosis of exclusion. The superficial ulceration pattern and lack of granulomas argue against Crohn's disease; absence of crypt distortion excludes refractory celiac disease; no history of NSAID use (standard exam convention) makes NSAID enteropathy less likely; and histology is inconsistent with lymphoma. Budesonide 9 mg daily is the established first-line therapy, with anti-TNF agents proving ineffective. Alternative options are appropriately discriminated: infliximab (A) is incorrect for non-transmural disease; stopping NSAIDs (B) is insufficient without NSAID history and would not treat established strictures; R-CHOP (D) is for lymphoma, which would show malignant infiltration; and cladribine (E) is for Type II refractory celiac, which requires villous atrophy. No contradictions or underspecification precludes a unique best answer. Minor improvement: explicitly state NSAID denial to remove any ambiguity.\",\"medical_accuracy_score\":   \"4\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. Key stem clues: 35-year-old woman with chronic iron deficiency anemia requiring recurrent IV iron, recurrent partial SBO, capsule endoscopy showing 5 short ulcerated strictures in proximal jejunum, and biopsies demonstrating superficial ulceration without granulomas, crypt distortion, or viral inclusions. These findings are classic for cryptogenic multifocal ulcerous stenosing enteritis (CMUSE), a diagnosis of exclusion. The superficial ulceration pattern and lack of granulomas argue against Crohn's disease; absence of crypt distortion excludes refractory celiac disease; no history of NSAID use (standard exam convention) makes NSAID enteropathy less likely; and histology is inconsistent with lymphoma. Budesonide 9 mg daily is the established first-line therapy, with anti-TNF agents proving ineffective. Alternative options are appropriately discriminated: infliximab (A) is incorrect for non-transmural disease; stopping NSAIDs (B) is insufficient without NSAID history and would not treat established strictures; R-CHOP (D) is for lymphoma, which would show malignant infiltration; and cladribine (E) is for Type II refractory celiac, which requires villous atrophy. No contradictions or underspecification precludes a unique best answer. Minor improvement: explicitly state NSAID denial to remove any ambiguity.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-015", "question": "A 45-year-old HIV-positive man on tenofovir DF/emtricitabine for 10 years presents with proximal muscle weakness, bone pain, and hypophosphatemia of 1.8 mg/dL. Urine studies show phosphaturia, glucosuria with normal blood glucose, and metabolic acidosis. What is the optimal electrolyte replacement regimen?", "options": ["A) Oral sodium phosphate 1 g TID alone", "B) Oral sodium phosphate plus calcitriol 0.25 mcg daily", "C) IV sodium phosphate 0.16 mmol/kg bolus then oral phosphate", "D) Oral sodium phosphate plus sodium bicarbonate 650 mg TID", "E) Stop tenofovir only"], "answer": "D", "answer_index": 3, "explanation": "Tenofovir-induced Fanconi syndrome causes proximal tubular loss of phosphate, glucose, and bicarbonate. Replacement requires both phosphate and bicarbonate to correct metabolic acidosis and prevent osteomalacia. Calcitriol is unnecessary if 25-OH vitamin D is normal; stopping tenofovir is necessary but insufficient for severe deficiency.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Nephrology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: V (Valid). Verdict: The keyed answer D is the correct best answer. The stem provides classic features of tenofovir-induced Fanconi syndrome: proximal muscle weakness, bone pain, hypophosphatemia with phosphaturia, glucosuria with normal blood glucose, and metabolic acidosis. These findings point to proximal tubular loss of phosphate and bicarbonate, requiring replacement of both. Option D (oral sodium phosphate plus sodium bicarbonate 650 mg TID) directly addresses both deficits. Alternative options are inferior: A and C replace phosphate alone, omitting bicarbonate; B adds unnecessary calcitriol when vitamin D status is unknown; E addresses the underlying drug but not the immediate electrolyte deficit. No internal contradictions or missing details prevent a single best answer. The regimen aligns with current management of tenofovir-associated Fanconi syndrome: discontinue tenofovir (acknowledged as necessary but not sufficient) and provide oral phosphate and bicarbonate supplementation. Dosing is typical for moderate hypophosphatemia and metabolic acidosis. No medical inaccuracies or outdated guidance are present. Minimal fix: none required.\",\n\"medical_accuracy_score\":  \t \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict: The keyed answer D is the correct best answer. The stem provides classic features of tenofovir-induced Fanconi syndrome: proximal muscle weakness, bone pain, hypophosphatemia with phosphaturia, glucosuria with normal blood glucose, and metabolic acidosis. These findings point to proximal tubular loss of phosphate and bicarbonate, requiring replacement of both. Option D (oral sodium phosphate plus sodium bicarbonate 650 mg TID) directly addresses both deficits. Alternative options are inferior: A and C replace phosphate alone, omitting bicarbonate; B adds unnecessary calcitriol when vitamin D status is unknown; E addresses the underlying drug but not the immediate electrolyte deficit. No internal contradictions or missing details prevent a single best answer. The regimen aligns with current management of tenofovir-associated Fanconi syndrome: discontinue tenofovir (acknowledged as necessary but not sufficient) and provide oral phosphate and bicarbonate supplementation. Dosing is typical for moderate hypophosphatemia and metabolic acidosis. No medical inaccuracies or outdated guidance are present. Minimal fix: none required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-016", "question": "A 70-year-old man with coronary artery disease is found to have clonal hematopoiesis of indeterminate potential (CHIP) with JAK2 V617F mutation at variant allele frequency of 12% on peripheral blood NGS. CBC is normal and there is no splenomegaly. What is his annual risk of thrombosis and recommended prophylaxis?", "options": ["A) 1% annual thrombosis risk; no prophylaxis needed", "B) 5% annual thrombosis risk; start hydroxyurea", "C) 0.5% annual thrombosis risk; start low-dose aspirin", "D) 10% annual thrombosis risk; start therapeutic enoxaparin", "E) No increased thrombosis risk; no prophylaxis"], "answer": "C", "answer_index": 2, "explanation": "CHIP with JAK2 V617F confers a 0.5-1% annual risk of thrombosis independent of traditional risk factors. Low-dose aspirin is recommended for primary prophylaxis. Progression to myelofibrosis or AML is rare (<1% annually). Hydroxyurea is not indicated without overt myeloproliferative neoplasm.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\": Validity label: V. Verdict: Correct best answer. Key stem clues: CHIP with JAK2 V617F (driver mutation), VAF 12%, normal CBC, no splenomegaly, and CAD comorbidity. These findings establish clonal hematopoiesis without overt MPN. Current data demonstrate JAK2-mutated CHIP confers ~0.5-1% annual thrombosis risk, with higher risk in those with cardiovascular disease. Option C correctly identifies this risk magnitude and recommends low-dose aspirin, which aligns with emerging expert consensus for primary prophylaxis in high-risk CHIP. Option A underestimates the benefit of prophylaxis despite similar risk estimate. Option B incorrectly suggests hydroxyurea, reserved for MPNs with proliferative features. Option D overstates risk and inappropriately recommends anticoagulation. Option E denies the established thrombotic association. No internal contradictions exist; the stem provides sufficient discrimination. Medical accuracy is strong but reflects evolving evidence rather than definitive guidelines. Minimal fix: Add qualifier \\\"based on current expert consensus\\\" to the aspirin recommendation, and specify \\\"if no contraindications\\\" given his CAD status.\",\"logical_false_reason\":\"T\",\"logical_validity\":true,\"medical_accuracy_score\":\"4\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": ": Validity label: V. Verdict: Correct best answer. Key stem clues: CHIP with JAK2 V617F (driver mutation), VAF 12%, normal CBC, no splenomegaly, and CAD comorbidity. These findings establish clonal hematopoiesis without overt MPN. Current data demonstrate JAK2-mutated CHIP confers ~0.5-1% annual thrombosis risk, with higher risk in those with cardiovascular disease. Option C correctly identifies this risk magnitude and recommends low-dose aspirin, which aligns with emerging expert consensus for primary prophylaxis in high-risk CHIP. Option A underestimates the benefit of prophylaxis despite similar risk estimate. Option B incorrectly suggests hydroxyurea, reserved for MPNs with proliferative features. Option D overstates risk and inappropriately recommends anticoagulation. Option E denies the established thrombotic association. No internal contradictions exist; the stem provides sufficient discrimination. Medical accuracy is strong but reflects evolving evidence rather than definitive guidelines. Minimal fix: Add qualifier \"based on current expert consensus\" to the aspirin recommendation, and specify \"if no contraindications\" given his CAD status.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-017", "question": "A 22-year-old man has recurrent sinopulmonary infections with Streptococcus pneumoniae, systemic lupus erythematosus-like malar rash, and low C1q level of 5 mg/dL (normal 10-25) with normal C1r and C1s. Genetic testing shows homozygous C1QA c.150C>G mutation. What is the recommended infection prophylaxis?", "options": ["A) Penicillin V 250 mg BID lifelong", "B) IVIG 400 mg/kg monthly", "C) No prophylaxis needed", "D) Posaconazole 300 mg daily", "E) Pneumococcal vaccine only"], "answer": "A", "answer_index": 0, "explanation": "C1q deficiency causes impaired classical pathway opsonization of encapsulated organisms and SLE-like autoimmunity. Lifelong penicillin prophylaxis is recommended to prevent invasive pneumococcal disease. IVIG is not indicated unless specific antibody deficiency coexists; fungal prophylaxis is unnecessary.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Immunology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. The homozygous C1q deficiency with recurrent pneumococcal infections and SLE-like features establishes a primary complement deficiency requiring bacterial prophylaxis. Key discriminating clues: genetic confirmation, recurrent encapsulated organism infections, and autoimmune manifestations. Option A is defensible because C1q deficiency impairs classical pathway opsonization, and lifelong penicillin prophylaxis follows standard practice for severe complement deficiencies with documented recurrences, analogous to asplenia protocols. Options B and D are incorrect—no evidence for IVIG without antibody deficiency, and fungal prophylaxis is inappropriate. Option C is unsafe given documented recurrences. Option E is insufficient as vaccination alone does not address the continuous functional defect when infections have already recurred; antibiotic prophylaxis provides ongoing protection. No medical inaccuracies: the pathophysiology and management align with current immunology consensus, though specific C1q deficiency guidelines are limited due to rarity. Minimal fix: explicitly state 'despite prior pneumococcal vaccination' to eliminate any ambiguity that vaccine alone (Option E) could be sufficient, making the necessity of antibiotic prophylaxis unequivocal.\",\"medical_accuracy_score\":4,\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The homozygous C1q deficiency with recurrent pneumococcal infections and SLE-like features establishes a primary complement deficiency requiring bacterial prophylaxis. Key discriminating clues: genetic confirmation, recurrent encapsulated organism infections, and autoimmune manifestations. Option A is defensible because C1q deficiency impairs classical pathway opsonization, and lifelong penicillin prophylaxis follows standard practice for severe complement deficiencies with documented recurrences, analogous to asplenia protocols. Options B and D are incorrect—no evidence for IVIG without antibody deficiency, and fungal prophylaxis is inappropriate. Option C is unsafe given documented recurrences. Option E is insufficient as vaccination alone does not address the continuous functional defect when infections have already recurred; antibiotic prophylaxis provides ongoing protection. No medical inaccuracies: the pathophysiology and management align with current immunology consensus, though specific C1q deficiency guidelines are limited due to rarity. Minimal fix: explicitly state 'despite prior pneumococcal vaccination' to eliminate any ambiguity that vaccine alone (Option E) could be sufficient, making the necessity of antibiotic prophylaxis unequivocal.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-018", "question": "A 68-year-old man on deferoxamine for transfusional iron overload (ferritin 3,500 ng/mL) develops a cavitary right upper lobe lung lesion. Biopsy shows broad nonseptate hyphae with right-angle branching. What is the optimal antifungal combination therapy?", "options": ["A) Liposomal amphotericin B 5 mg/kg/day alone", "B) Amphotericin B plus posaconazole 300 mg daily", "C) Isavuconazole 372 mg daily", "D) Amphotericin B plus deferasirox 20 mg/kg daily", "E) Caspofungin 50 mg daily plus posaconazole"], "answer": "D", "answer_index": 3, "explanation": "Deferoxamine is a siderophore that enhances mucoraceal growth and must be stopped. Deferasirox has intrinsic antifungal activity against Mucorales. Liposomal amphotericin B is first-line; combination with deferasirox improves outcomes. Isavuconazole is second-line monotherapy; caspofungin has minimal activity.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: K (Miskeyed) – the item keys a combination of amphotericin B plus deferasirox as optimal for mucormycosis, but current IDSA guidelines recommend high‑dose liposomal amphotericin B monotherapy. Deferasirox adjunct remains investigational; robust outcome data are lacking. The stem’s key discriminators (cavitary lesion, broad non‑septate hyphae at right angles, deferoxamine use, ferritin 3500 ng/mL) correctly point to Mucorales infection, and the question asks for a combination regimen. Among the choices, only D addresses iron overload, but the claim that this combination is optimal is not supported, making the keyed answer misaligned with standard care. Alternatives: A is correct monotherapy but not a combination; B and E lack evidence; C is second‑line monotherapy. Because the keyed answer does not reflect accepted best practice, the item is miskeyed. Medical accuracy score 2 – the rationale overstates deferasirox benefit and contradicts current guidelines. Minimal fix: Change the key to A and revise the stem to ask for 'initial therapy' rather than 'combination therapy', or remove deferasirox and add a proven second antifungal if a combination is desired.\",\"medical_accuracy_score\":2,\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: K (Miskeyed) – the item keys a combination of amphotericin B plus deferasirox as optimal for mucormycosis, but current IDSA guidelines recommend high‑dose liposomal amphotericin B monotherapy. Deferasirox adjunct remains investigational; robust outcome data are lacking. The stem’s key discriminators (cavitary lesion, broad non‑septate hyphae at right angles, deferoxamine use, ferritin 3500 ng/mL) correctly point to Mucorales infection, and the question asks for a combination regimen. Among the choices, only D addresses iron overload, but the claim that this combination is optimal is not supported, making the keyed answer misaligned with standard care. Alternatives: A is correct monotherapy but not a combination; B and E lack evidence; C is second‑line monotherapy. Because the keyed answer does not reflect accepted best practice, the item is miskeyed. Medical accuracy score 2 – the rationale overstates deferasirox benefit and contradicts current guidelines. Minimal fix: Change the key to A and revise the stem to ask for 'initial therapy' rather than 'combination therapy', or remove deferasirox and add a proven second antifungal if a combination is desired.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-019", "question": "A 62-year-old woman with high-grade serous ovarian cancer develops subacute cerebellar ataxia, dysarthria, and nystagmus over 3 weeks. Anti-Yo antibodies are positive at titer 1:10,240 in serum and CSF. CSF shows lymphocytic pleocytosis (50 cells/μL). What is the immunotherapy protocol?", "options": ["A) Methylprednisolone 1 g IV x3 days then prednisone 1 mg/kg", "B) IVIG 2 g/kg monthly", "C) Cyclophosphamide 750 mg/m2 monthly plus prednisone", "D) Rituximab 375 mg/m2 weekly x4 plus prednisone", "E) Tumor debulking surgery only"], "answer": "C", "answer_index": 2, "explanation": "Anti-Yo associated paraneoplastic cerebellar degeneration is B-cell mediated; cyclophosphamide crosses the blood-brain barrier and depletes plasma cells more effectively than rituximab. Combined with steroids, it stabilizes neurologic decline. IVIG is less effective for anti-Yo; tumor treatment alone is insufficient.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Medical Oncology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: Multiple answers defensible (M), secondary Underspecified (U). The question asks for 'the immunotherapy protocol' for anti-Yo paraneoplastic cerebellar degeneration (PCD), implying a single standard regimen. However, no consensus protocol exists; immunotherapy is often ineffective. Key stem clues (subacute cerebellar signs, high-titer anti-Yo, CSF pleocytosis) correctly point to anti-Yo PCD, but fail to specify disease severity, prior therapy, or treatment goals. The keyed answer (cyclophosphamide) is biologically plausible given plasma cell-mediated pathophysiology and CNS penetration, but this is not established superiority over other options. Option A (high-dose steroids) and Option B (IVIG) are equally defensible as first-line approaches per standard neuroimmunology practice. Option D (rituximab) is also used despite limited plasma cell activity. The explanation's claim that cyclophosphamide 'depletes plasma cells more effectively' and 'stabilizes neurologic decline' overstates evidence; most data show poor response to any immunotherapy. Medical accuracy is compromised by presenting a non-standard regimen as definitive protocol. Minor fix: Change stem to 'Which of the following is the most appropriate initial immunotherapy to consider?' and revise explanation to acknowledge lack of consensus.\",\"medical_accuracy_score\":   \"3\",\"logical_validity\": false,\"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: Multiple answers defensible (M), secondary Underspecified (U). The question asks for 'the immunotherapy protocol' for anti-Yo paraneoplastic cerebellar degeneration (PCD), implying a single standard regimen. However, no consensus protocol exists; immunotherapy is often ineffective. Key stem clues (subacute cerebellar signs, high-titer anti-Yo, CSF pleocytosis) correctly point to anti-Yo PCD, but fail to specify disease severity, prior therapy, or treatment goals. The keyed answer (cyclophosphamide) is biologically plausible given plasma cell-mediated pathophysiology and CNS penetration, but this is not established superiority over other options. Option A (high-dose steroids) and Option B (IVIG) are equally defensible as first-line approaches per standard neuroimmunology practice. Option D (rituximab) is also used despite limited plasma cell activity. The explanation's claim that cyclophosphamide 'depletes plasma cells more effectively' and 'stabilizes neurologic decline' overstates evidence; most data show poor response to any immunotherapy. Medical accuracy is compromised by presenting a non-standard regimen as definitive protocol. Minor fix: Change stem to 'Which of the following is the most appropriate initial immunotherapy to consider?' and revise explanation to acknowledge lack of consensus.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251221T010349114Z_kimi-k2-thinking_seed131", "question_id": "20251221T010349114Z_kimi-k2-thinking_seed131-020", "question": "A 35-year-old man develops fever, facial edema, diffuse erythematous rash covering 60% BSA, eosinophilia of 2,200/μL, and atypical lymphocytes 3 weeks after starting allopurinol 300 mg daily for gout. AST is 850 U/L and ALT is 620 U/L. What is the appropriate corticosteroid regimen?", "options": ["A) Prednisone 1 mg/kg PO daily, taper over 2 weeks", "B) Methylprednisolone 1-2 mg/kg IV, slow taper over 8-12 weeks", "C) Methylprednisolone 1 g IV x3 days only", "D) No steroids; antihistamines and topical therapy", "E) Topical triamcinolone 0.1% BSA"], "answer": "B", "answer_index": 1, "explanation": "DRESS syndrome with hepatitis requires high-dose systemic steroids; rapid taper risks relapse and rebound hepatitis. Slow taper over 8-12 weeks with monitoring for viral reactivation (HHV-6) is standard. Pulse therapy alone is insufficient; antihistamines are adjunctive only.", "generator_model": "kimi-k2-thinking", "seed": 131, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Allergy/Immunology", "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V (Valid). Verdict: Correct best answer. The vignette describes DRESS syndrome with severe hepatitis (AST 850 U/L, ALT 620 U/L), marked eosinophilia (2,200/μL), diffuse rash covering 60% BSA, fever, and facial edema occurring three weeks after initiating allopurinol. These findings fulfill the RegiSCAR criteria for DRESS and indicate systemic organ involvement that mandates high-dose systemic corticosteroids. Option B (methylprednisolone 1-2 mg/kg IV, slow taper over 8-12 weeks) aligns with current guidelines recommending prolonged steroid courses to prevent relapse and rebound hepatitis. Option A’s oral prednisone 1 mg/kg with a 2-week taper is too brief and risks recurrence; Option C’s 3-day pulse lacks maintenance therapy; Options D and E are insufficient for systemic disease. The stem provides all necessary discriminators, and no internal contradictions exist. Medical accuracy: The regimen reflects standard-of-care management of severe DRESS, including monitoring for viral reactivation (HHV-6). No major inaccuracies or outdated recommendations. Minimal fix: None required.\",\n\"medical_accuracy_score\":  \t \t \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The vignette describes DRESS syndrome with severe hepatitis (AST 850 U/L, ALT 620 U/L), marked eosinophilia (2,200/μL), diffuse rash covering 60% BSA, fever, and facial edema occurring three weeks after initiating allopurinol. These findings fulfill the RegiSCAR criteria for DRESS and indicate systemic organ involvement that mandates high-dose systemic corticosteroids. Option B (methylprednisolone 1-2 mg/kg IV, slow taper over 8-12 weeks) aligns with current guidelines recommending prolonged steroid courses to prevent relapse and rebound hepatitis. Option A’s oral prednisone 1 mg/kg with a 2-week taper is too brief and risks recurrence; Option C’s 3-day pulse lacks maintenance therapy; Options D and E are insufficient for systemic disease. The stem provides all necessary discriminators, and no internal contradictions exist. Medical accuracy: The regimen reflects standard-of-care management of severe DRESS, including monitoring for viral reactivation (HHV-6). No major inaccuracies or outdated recommendations. Minimal fix: None required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]